Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema.
OBJECTIVE
To evaluate the effect of intravitreal triamcinolone acetonide on serous macular detachment in eyes with diabetic macular edema.


METHODS
Interventional case series.


METHODS
The study population comprised twenty eyes of 20 patients with diabetic macular edema (12 men, eight women), aged 48 to 76 years. The eligibility criteria for this study included clinically detectable macular edema in which the presence of serous macular detachment was documented by optical coherence tomography. After intravitreal injection of 0.1 ml (4 mg) triamcinolone acetonide, visual and anatomic responses were observed.


RESULTS
In all eyes, after an injection of triamcinolone acetonide, macular edema and serous macular detachment regressed. At 3 and 6 months, macular edema and serous macular detachment had recurred in eight (40%) and nine eyes (45%), respectively. Patients with recurrence were re-treated. No eyes lost vision at 1 month, and all eyes showed improvement. At 3 months, no eyes had lost vision from baseline, and 17 eyes (85%) showed improvement. At 6 months, again no eyes had lost vision from baseline, and 16 eyes (80%) maintained improved visual acuity.


CONCLUSIONS
Intravitreal triamcinolone acetonide is an effective treatment for serous macular detachment in patients with diabetic macular edema.
Ozdemir
Hakan
H
Istanbul Retina Institute Inc, Istanbul, Turkey.
Karacorlu
Murat
M
Karacorlu
Serra Arf
SA
D000368:Aged; D001769:Blood; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D012008:Recurrence; D012163:Retinal Detachment / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide